ReviewFrontiers in pharmacology2021
RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.
Hajime Honjo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this papercites it
ReviewFrontiers in pharmacology2021
Hajime Honjo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.